Biogen | BIIB - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Acadia Pharmaceuticals USD 0 4.12M 2024-09
ALKERMES USD 25.92M 5.03M 2026-06
Amgen USD 95.64B 94.98B 2026-06
Bayer EUR 675M 87M 2025-12
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 14.96M 12.18M 2026-03
Bristol-Myers Squibb USD 407M 4M 2026-06
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 247M 7M 2026-06
Incyte USD 582K 13K 2026-06
Merck USD 525M 46M 2026-06
Moderna USD 10.96B 527M 2026-06
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 462M 119M 2026-06
Pfizer USD 667M 4M 2026-06
PTC Therapeutics USD 3.25B 381.37M 2026-06
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR 287M 109M 2026-06
Sanofi EUR -25M 99.78M 2025-12
Sarepta Therapeutics USD 21.51M 205K 2026-06
Teva Pharmaceutical Industries USD 195M 21M 2026-06
Ultragenyx Pharmaceutical USD 22M 1000K 2026-06
United Therapeutics USD 2.9M 200K 2026-06
Vertex Pharmaceuticals USD 3.3M 0 2025-12